Clinical trial
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC…
NCT00389675 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00389675 |
|---|---|
| Title | DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension |
| Official title | A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E) |
| Acronym | Darusentan |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Darusentan, Guanfacine |
| Enrollment | 661 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Oct 19, 2006 |
| Last update posted | Jan 6, 2014 |
| Countries | Argentina, Australia, Brazil, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: